Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

significant disability when compared to patients treated with interferon beta-1a. This difference was statistically significant in favor of the alemtuzumab patients with a p-value less than the pre-specified value (p=0.01646) assigned for the three-year analysis.

Results for the secondary endpoints support the findings seen in the co- primary endpoints. Full, detailed efficacy and safety data from the study are expected to be presented at the 60th Annual Meeting of the American Academy of Neurology next spring.

"These results demonstrate the durability of the previously reported effect of alemtuzumab for the treatment of multiple sclerosis that, by our analysis, exceeds any current marketed products and anything that we can see in development," said Richard A. Moscicki, MD, chief medical officer for Genzyme. "We are very impressed with the consistency of these data and feel that they continue to point to the strong likelihood of alemtuzumab being approved for MS patients."

Safety Data: No New Cases of ITP

A total of six patients have been diagnosed with ITP associated with Grade 3 or 4 thrombocytopenia in this trial and there have been no new cases of ITP reported in the past year in this study.

Common non-serious adverse events included infusion reactions in the alemtuzumab patients and flu-like symptoms in patients using interferon beta- 1a. Severe infections were infrequent in the alemtuzumab patients and were resolved with or without an intervention. The incidence of all thyroid adverse events, including Graves' disease, was less than expected compared to early reports in the literature on the use of alemtuzumab in MS.

Two Phase 3 studies have recently begun examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis. Genzyme and Bayer Schering Pharma AG, Germany announced last month the start of the CARE-MS I trial (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis), a randomized
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
(Date:12/22/2014)... 22, 2014 NxStage Medical, Inc. (NASDAQ: ... dialysis products, announced today that the U.S. Food ... One™ to perform hemodialysis overnight while the patient ... hemodialysis. NxStage,s® System One is the first and ... this indication. Home nocturnal hemodialysis ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research ... announced the addition of the "Investment Analysis ... report to their offering. ... investments in the US medical device sector identifies ... equity and venture capital investments, and mergers and ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2
... REDWOOD CITY, Calif., May 18, 2011 Genomic Health, ... the company will present results from ten separate studies ... Meeting, taking place June 3-7, 2011 at McCormick Place ... DX® breast cancer test, which is clinically validated ...
... Dendreon Corporation (Nasdaq: DNDN ) today ... at the 2011 American Society of Clinical Oncology annual ... to Disease-Related Pain After Sipuleucel-T in Asymptomatic Patients with ... Phase 3 Trials," abstract #4661. McCormick Place Hall A ...
Cached Medicine Technology:Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 7Dendreon Announces Presentation of PROVENGE Data at the 2011 American Society of Clinical Oncology Annual Meeting 2Dendreon Announces Presentation of PROVENGE Data at the 2011 American Society of Clinical Oncology Annual Meeting 3Dendreon Announces Presentation of PROVENGE Data at the 2011 American Society of Clinical Oncology Annual Meeting 4
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... among people who have mild memory loss, and they can ... largest ever investigation into heart disease and stroke in those ... some of who had a MRI scan which could indicate ... at Wake Forest University now report on this sub-group, observing ...
... been at a loss when it comes to health issues. ... tobacco smoke for residents. Environmental tobacco smoke// (ETS, or passive ... - from exacerbation of asthma to eye irritation and even ... workplace and in public places. Researchers at the University of ...
... new study, researchers found that the treatment naltrexone is ... abuse. Researchers of alcohol often distinguish two patterns of ... drinking are saved up for the weekend and holidays, ... regularly and often with meals. The Anglo-Saxon pattern has ...
... new study, children of people with mood disorders who have ... own lives as well. The link is especially strong among ... who suffer from mood disorders themselves. ,Research has shown ... risk of committing suicide, but few studies have looked at ...
... they have observed that postmenopausal women who use estrogen are ... tissue change in the joints that causes pain in that ... over 40 years old. Experts estimate up to 70 percent ... conducted a study to see if estrogen plays a role ...
... a clot-buster injection may unclog a mechanical heart pump, ... from University Hospital in Germany,// felt that this is ... heart failure patients who receive left ventricular assist devices. ... pump-like device that is surgically implanted to maintain the ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: